GLAND Q2 FY27 ; CONS NET PROFIT UP 58.29% AT ₹290.76 CR (YOY), DOWN 8.27% (QOQ)

REVENUE UP 23.32% AT ₹1833.59 CR (YOY), UP 1.85% (QOQ) EBITDA UP 54.21% AT ₹484.04 CR (YOY), DOWN 1.09% (QOQ) MARGINS AT 26.40% VS 21.11% (YOY), 27.18% (QOQ)

Gland Pharma Limited

Open attachment

← Back to feed